Finding Solutions in Advanced NSCLC Without Driver Mutations: Jamie E. Chaft, MD

​Many patients with non-small cell lung cancer (NSCLC) present with advanced disease, which is highly resistant to chemotherapy. Recently, the use of tumor histology and relevant molecular biomarkers in determining optimal treatment strategies has improved outcomes for some patients, yet a number of targeted therapies are not applicable to patients without driver mutations. In this interview with i3 Health, Jamie E. Chaft, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center and an...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.